TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06569147: Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Sponsor: Dana-Farber Cancer Institute · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 49 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$761,940

Rescue Site Savings

+$507,960

Unlock Full NCT06569147 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06569147 Rescue Dossier →